O	0	4	Type	Type	NN	B-NP
O	4	5	-	-	HYPH	I-NP
O	5	6	A	A	NN	I-NP
O	7	22	cholecystokinin	cholecystokinin	NN	I-NP
O	23	32	receptors	receptor	NNS	I-NP
O	33	35	in	in	IN	B-PP
B-Cell	36	42	CHP212	CHP212	NN	B-NP
I-Cell	43	56	neuroblastoma	neuroblastoma	NN	I-NP
I-Cell	57	62	cells	cell	NNS	I-NP
O	62	63	:	:	:	O
O	64	72	evidence	evidence	NN	B-NP
O	73	76	for	for	IN	B-PP
O	77	88	association	association	NN	B-NP
O	89	93	with	with	IN	B-PP
O	94	95	G	G	NN	B-NP
O	96	103	protein	protein	NN	I-NP
O	104	107	and	and	CC	O
O	108	118	activation	activation	NN	B-NP
O	119	121	of	of	IN	B-PP
O	122	138	phosphoinositide	phosphoinositide	NN	B-NP
O	139	149	hydrolysis	hydrolysis	NN	I-NP
O	149	150	.	.	.	O

O	151	155	125I	125I	CD	B-NP
O	155	156	-	-	HYPH	I-NP
O	156	162	Bolton	Bolton	NNP	I-NP
O	163	169	Hunter	Hunter	NNP	I-NP
O	169	170	-	-	HYPH	B-VP
O	170	185	cholecystokinin	cholecystokinin	NN	B-NP
O	186	197	octapeptide	octapeptide	NN	I-NP
O	198	199	(	(	(	O
O	199	201	BH	BH	NN	B-NP
O	201	202	-	-	HYPH	B-NP
O	202	206	CCK8	CCK8	NN	I-NP
O	206	207	)	)	)	O
O	208	211	and	and	CC	O
O	212	213	(	(	(	O
O	213	214	-	-	SYM	O
O	214	215	)	)	)	O
O	215	216	-	-	HYPH	B-NP
O	216	217	[	[	(	I-NP
O	217	219	3H	3H	NN	I-NP
O	219	220	]	]	)	I-NP
O	220	221	L	L	NN	I-NP
O	221	222	-	-	HYPH	B-NP
O	222	228	364718	364718	CD	I-NP
B-Cellular_component	229	237	membrane	membrane	NN	I-NP
O	238	245	binding	binding	NN	I-NP
O	246	252	assays	assay	NNS	I-NP
O	253	257	were	be	VBD	B-VP
O	258	262	used	use	VBN	I-VP
O	263	265	to	to	TO	B-VP
O	266	274	identify	identify	VB	I-VP
O	275	278	and	and	CC	I-VP
O	279	291	characterize	characterize	VB	I-VP
O	292	307	cholecystokinin	cholecystokinin	NN	B-NP
O	308	309	(	(	(	O
O	309	312	CCK	CCK	NN	B-NP
O	312	313	)	)	)	O
O	314	323	receptors	receptor	NNS	B-NP
O	324	326	in	in	IN	B-PP
B-Cell	327	333	CHP212	CHP212	NN	B-NP
O	334	339	human	human	JJ	I-NP
B-Cell	340	353	neuroblastoma	neuroblastoma	NN	I-NP
I-Cell	354	359	cells	cell	NNS	I-NP
O	359	360	.	.	.	O

O	361	364	The	The	DT	B-NP
O	365	371	ligand	ligand	NN	I-NP
O	372	379	binding	binding	NN	I-NP
O	380	390	properties	property	NNS	I-NP
O	391	393	of	of	IN	B-PP
O	394	397	CCK	CCK	NN	B-NP
O	398	407	receptors	receptor	NNS	I-NP
O	408	410	in	in	IN	B-PP
O	411	416	these	these	DT	B-NP
B-Cell	417	422	cells	cell	NNS	I-NP
O	423	426	are	be	VBP	B-VP
O	427	434	similar	similar	JJ	B-ADJP
O	435	437	to	to	TO	B-PP
O	438	443	those	those	DT	B-NP
O	444	449	found	find	VBN	B-VP
O	450	452	in	in	IN	B-PP
B-Organ	453	461	pancreas	pancreas	NN	B-NP
O	462	463	(	(	(	O
O	463	466	CCK	CCK	NN	B-NP
O	466	467	-	-	HYPH	B-NP
O	467	468	A	A	NN	I-NP
O	469	474	sites	site	NNS	I-NP
O	474	475	)	)	)	O
O	476	479	and	and	CC	O
O	480	486	differ	differ	VBP	B-VP
O	487	491	from	from	IN	B-PP
O	492	495	the	the	DT	B-NP
O	496	507	predominant	predominant	JJ	I-NP
O	508	512	type	type	NN	I-NP
O	513	515	of	of	IN	B-PP
O	516	519	CCK	CCK	NN	B-NP
O	520	527	binding	binding	NN	I-NP
O	528	532	site	site	NN	I-NP
O	533	538	found	find	VBN	B-VP
O	539	541	in	in	IN	B-PP
B-Organ	542	547	brain	brain	NN	B-NP
O	548	549	(	(	(	O
O	549	552	CCK	CCK	NN	B-NP
O	552	553	-	-	HYPH	B-NP
O	553	554	B	B	NN	I-NP
O	555	560	sites	site	NNS	I-NP
O	560	561	)	)	)	O
O	561	562	.	.	.	O

O	563	566	The	The	DT	B-NP
O	567	575	specific	specific	JJ	I-NP
O	576	583	binding	binding	NN	I-NP
O	584	586	of	of	IN	B-PP
O	587	591	125I	125I	NN	B-NP
O	591	592	-	-	HYPH	B-NP
O	592	594	BH	BH	NN	I-NP
O	594	595	-	-	HYPH	B-NP
O	595	599	CCK8	CCK8	NN	I-NP
O	600	603	but	but	CC	O
O	604	607	not	not	RB	O
O	608	609	(	(	(	O
O	609	610	-	-	SYM	O
O	610	611	)	)	)	O
O	611	612	-	-	HYPH	B-NP
O	612	613	[	[	(	I-NP
O	613	615	3H	3H	NN	I-NP
O	615	616	]	]	)	I-NP
O	616	617	L	L	NN	I-NP
O	617	618	-	-	HYPH	O
O	618	624	364718	364718	CD	B-NP
O	625	628	was	be	VBD	B-VP
O	629	636	reduced	reduce	VBN	I-VP
O	637	639	by	by	IN	B-PP
O	640	643	the	the	DT	B-NP
O	644	657	metabolically	metabolically	RB	I-NP
O	658	664	stable	stable	JJ	I-NP
O	665	668	GTP	GTP	NN	I-NP
O	669	675	analog	analog	NN	I-NP
O	676	685	guanosine	guanosine	NN	I-NP
O	686	687	5	5	CD	I-NP
O	687	688	'	'	SYM	I-NP
O	688	689	-	-	HYPH	I-NP
O	689	690	(	(	(	O
O	690	694	beta	beta	SYM	B-NP
O	694	695	-	-	HYPH	B-NP
O	695	700	delta	delta	SYM	I-NP
O	700	701	-	-	HYPH	I-NP
O	701	706	imido	imido	NN	I-NP
O	706	707	)	)	)	O
O	707	720	trisphosphate	trisphosphate	NN	B-NP
O	720	721	.	.	.	O

O	722	723	A	A	DT	B-NP
O	724	735	substantial	substantial	JJ	I-NP
O	736	746	difference	difference	NN	I-NP
O	747	749	in	in	IN	B-PP
O	750	753	the	the	DT	B-NP
O	754	758	Bmax	Bmax	NN	I-NP
O	759	762	for	for	IN	B-PP
O	763	766	the	the	DT	B-NP
O	767	779	radiolabeled	radiolabele	VBN	I-NP
O	780	787	agonist	agonist	NN	I-NP
O	788	789	(	(	(	O
O	789	793	125I	125I	NN	B-NP
O	793	794	-	-	HYPH	B-NP
O	794	796	BH	BH	NN	I-NP
O	796	797	-	-	HYPH	B-NP
O	797	801	CCK8	CCK8	NN	I-NP
O	801	802	)	)	)	O
O	803	806	and	and	CC	O
O	807	817	antagonist	antagonist	NN	B-NP
O	818	819	[	[	(	O
O	819	820	(	(	(	O
O	820	821	-	-	SYM	O
O	821	822	)	)	)	O
O	822	823	-	-	HYPH	B-NP
O	823	824	[	[	(	I-NP
O	824	826	3H	3H	NN	I-NP
O	826	827	]	]	)	I-NP
O	827	828	L	L	NN	I-NP
O	828	829	-	-	HYPH	B-NP
O	829	835	364718	364718	CD	I-NP
O	835	836	]	]	)	O
O	837	840	was	be	VBD	B-VP
O	841	846	noted	note	VBN	I-VP
O	846	847	.	.	.	O

O	848	853	These	These	DT	B-NP
O	854	866	observations	observation	NNS	I-NP
O	867	870	are	be	VBP	B-VP
O	871	881	consistent	consistent	JJ	B-ADJP
O	882	886	with	with	IN	B-PP
O	887	890	CCK	CCK	NN	B-NP
O	891	900	receptors	receptor	NNS	I-NP
O	901	909	existing	exist	VBG	B-VP
O	910	912	in	in	IN	B-PP
O	913	920	guanine	guanine	NN	B-NP
O	921	931	nucleotide	nucleotide	NN	I-NP
O	931	932	-	-	HYPH	O
O	932	939	binding	bind	VBG	B-NP
O	940	947	protein	protein	NN	I-NP
O	947	948	-	-	HYPH	O
O	948	955	coupled	couple	VBN	B-VP
O	956	959	and	and	CC	O
O	960	961	-	-	HYPH	B-NP
O	961	970	uncoupled	uncoupled	JJ	I-NP
O	971	977	states	state	NNS	I-NP
O	977	978	.	.	.	O

O	979	986	Similar	Similar	JJ	B-ADJP
O	987	989	to	to	TO	B-PP
O	990	993	its	its	PRP$	B-NP
O	994	1000	action	action	NN	I-NP
O	1001	1003	in	in	IN	B-PP
B-Cell	1004	1014	pancreatic	pancreatic	JJ	B-NP
I-Cell	1015	1021	acinar	acinar	JJ	I-NP
I-Cell	1022	1027	cells	cell	NNS	I-NP
O	1027	1028	,	,	,	O
O	1029	1033	CCK8	CCK8	NN	B-NP
O	1033	1034	(	(	(	O
O	1034	1035	S	S	NN	B-NP
O	1035	1036	)	)	)	O
O	1037	1047	stimulated	stimulate	VBD	B-VP
O	1048	1051	the	the	DT	B-NP
O	1052	1064	accumulation	accumulation	NN	I-NP
O	1065	1067	of	of	IN	B-PP
O	1068	1069	[	[	(	O
O	1069	1071	3H	3H	NN	B-NP
O	1071	1072	]	]	)	O
O	1072	1080	inositol	inositol	NN	B-NP
O	1081	1091	phosphates	phosphate	NNS	I-NP
O	1092	1094	in	in	IN	B-PP
B-Cell	1095	1100	cells	cell	NNS	B-NP
O	1101	1111	prelabeled	prelabele	VBN	B-VP
O	1112	1116	with	with	IN	B-PP
O	1117	1118	[	[	(	O
O	1118	1120	3H	3H	NN	B-NP
O	1120	1121	]	]	)	O
O	1121	1124	myo	myo	AFX	O
O	1124	1125	-	-	HYPH	O
O	1125	1133	inositol	inositol	NN	B-NP
O	1134	1135	(	(	(	O
O	1135	1139	EC50	EC50	NN	B-NP
O	1140	1141	=	=	SYM	B-VP
O	1142	1143	3	3	CD	B-NP
O	1143	1144	.	.	SYM	I-NP
O	1144	1145	2	2	CD	I-NP
O	1146	1147	+	+	SYM	O
O	1147	1148	/	/	SYM	B-NP
O	1148	1149	-	-	SYM	B-NP
O	1150	1151	0	0	CD	B-NP
O	1151	1152	.	.	.	I-NP
O	1152	1153	4	4	CD	I-NP
O	1154	1156	nM	nM	NN	I-NP
O	1156	1157	;	;	:	O
O	1158	1165	maximum	maximum	JJ	B-NP
O	1166	1174	response	response	NN	I-NP
O	1175	1176	=	=	SYM	B-VP
O	1177	1178	4	4	CD	B-NP
O	1178	1179	.	.	SYM	I-NP
O	1179	1180	5	5	CD	I-NP
O	1181	1182	+	+	SYM	O
O	1182	1183	/	/	SYM	O
O	1183	1184	-	-	SYM	B-NP
O	1185	1186	0	0	CD	B-NP
O	1186	1187	.	.	.	I-NP
O	1187	1188	4	4	CD	I-NP
O	1189	1190	x	x	CC	O
O	1191	1196	basal	basal	JJ	B-NP
O	1196	1197	)	)	)	O
O	1197	1198	.	.	.	O

O	1199	1202	The	The	DT	B-NP
O	1203	1212	intrinsic	intrinsic	JJ	I-NP
O	1213	1221	activity	activity	NN	I-NP
O	1222	1224	of	of	IN	B-PP
O	1225	1228	CCK	CCK	NN	B-NP
O	1229	1238	analogues	analogue	NNS	I-NP
O	1239	1241	in	in	IN	B-PP
O	1242	1253	stimulating	stimulate	VBG	B-VP
O	1254	1270	phosphoinositide	phosphoinositide	NN	B-NP
O	1271	1281	hydrolysis	hydrolysis	NN	I-NP
O	1282	1285	was	be	VBD	B-VP
O	1286	1299	substantially	substantially	RB	B-ADJP
O	1300	1304	less	less	JJR	I-ADJP
O	1305	1309	than	than	IN	B-PP
O	1310	1315	their	their	PRP$	B-NP
O	1316	1324	reported	report	VBN	I-NP
O	1325	1334	intrinsic	intrinsic	JJ	I-NP
O	1335	1343	activity	activity	NN	I-NP
O	1344	1346	in	in	IN	B-PP
O	1347	1358	stimulating	stimulate	VBG	B-VP
O	1359	1375	phosphoinositide	phosphoinositide	NN	B-NP
O	1376	1386	hydrolysis	hydrolysis	NN	I-NP
O	1387	1389	in	in	IN	B-PP
B-Cell	1390	1400	pancreatic	pancreatic	JJ	B-NP
I-Cell	1401	1407	acinar	acinar	JJ	I-NP
I-Cell	1408	1413	cells	cell	NNS	I-NP
O	1413	1414	.	.	.	O

O	1415	1418	The	The	DT	B-NP
B-Cell	1419	1425	CHP212	CHP212	NN	I-NP
I-Cell	1426	1439	neuroblastoma	neuroblastoma	NN	I-NP
I-Cell	1440	1444	cell	cell	NN	I-NP
O	1445	1448	may	may	MD	B-VP
O	1449	1454	serve	serve	VB	I-VP
O	1455	1457	as	as	IN	B-PP
O	1458	1459	a	a	DT	B-NP
O	1460	1466	useful	useful	JJ	I-NP
O	1467	1472	model	model	NN	I-NP
O	1473	1476	for	for	IN	B-PP
O	1477	1480	the	the	DT	B-NP
O	1481	1489	recently	recently	RB	I-NP
O	1490	1498	reported	report	VBN	I-NP
O	1499	1502	CCK	CCK	NN	I-NP
O	1502	1503	-	-	HYPH	I-NP
O	1503	1504	A	A	NN	I-NP
O	1505	1512	binding	binding	NN	I-NP
O	1513	1517	site	site	NN	I-NP
O	1518	1523	found	find	VBN	B-VP
O	1524	1526	in	in	IN	B-PP
O	1527	1530	the	the	DT	B-NP
B-Anatomical_system	1531	1538	central	central	JJ	I-NP
I-Anatomical_system	1539	1546	nervous	nervous	JJ	I-NP
I-Anatomical_system	1547	1553	system	system	NN	I-NP
O	1553	1554	.	.	.	O

